Kenvue Inc. (NYSE:KVUE) Shares Bought by Summit Trail Advisors LLC

Summit Trail Advisors LLC grew its position in shares of Kenvue Inc. (NYSE:KVUE) by 60.4% in the 4th quarter, Holdings Channel.com reports. The firm owned 17,651 shares of the company’s stock after buying an additional 6,646 shares during the period. Summit Trail Advisors LLC’s holdings in Kenvue were worth $377,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. AMF Tjanstepension AB raised its stake in shares of Kenvue by 187.3% during the 3rd quarter. AMF Tjanstepension AB now owns 120,477 shares of the company’s stock worth $2,787,000 after buying an additional 78,540 shares during the period. Exchange Traded Concepts LLC increased its holdings in Kenvue by 371.7% in the 3rd quarter. Exchange Traded Concepts LLC now owns 29,887 shares of the company’s stock worth $691,000 after acquiring an additional 23,551 shares in the last quarter. Vontobel Holding Ltd. raised its position in Kenvue by 13.4% during the third quarter. Vontobel Holding Ltd. now owns 22,594 shares of the company’s stock worth $523,000 after acquiring an additional 2,677 shares during the period. LaFleur & Godfrey LLC lifted its holdings in Kenvue by 12.5% during the third quarter. LaFleur & Godfrey LLC now owns 62,650 shares of the company’s stock valued at $1,449,000 after purchasing an additional 6,985 shares in the last quarter. Finally, Wolff Wiese Magana LLC grew its position in shares of Kenvue by 0.7% in the third quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock valued at $1,781,000 after purchasing an additional 501 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Stock Performance

NYSE:KVUE opened at $20.96 on Thursday. The company’s 50-day moving average is $21.41 and its two-hundred day moving average is $22.03. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The firm has a market capitalization of $40.19 billion, a price-to-earnings ratio of 39.55, a PEG ratio of 2.16 and a beta of 1.45.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Analysts forecast that Kenvue Inc. will post 1.05 EPS for the current year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be issued a $0.205 dividend. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.91%. Kenvue’s dividend payout ratio (DPR) is currently 154.72%.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on KVUE. UBS Group decreased their price target on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research note on Friday, February 7th. Royal Bank of Canada restated a “sector perform” rating and issued a $24.00 target price on shares of Kenvue in a research report on Monday, February 3rd. Citigroup dropped their price target on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Wednesday, January 15th. Deutsche Bank Aktiengesellschaft lowered Kenvue from a “buy” rating to a “hold” rating and decreased their price objective for the company from $25.00 to $24.00 in a report on Thursday, December 12th. Finally, Canaccord Genuity Group dropped their target price on shares of Kenvue from $27.00 to $24.00 and set a “buy” rating for the company in a report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Kenvue currently has a consensus rating of “Hold” and a consensus target price of $23.00.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.